NL-OMON44644已完成不适用
A single dose, randomized, four-way cross-over, bioavailability and food interaction study of PedPRM (Pediatric Prolonged Release Melatonin, Neurim Pharmaceuticals Ltd) and Circadin® tablets in healthy male and female volunteers. - PedPRM bioavailability and food interaction study.
eurim Pharmaceuticals Ltd0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Signed informed consent prior to any study-mandated procedure.
- •2. Healthy male or female subjects, 18 to 55 years of age, inclusive at screening.
- •3. Body mass index (BMI) between 18 and 30 kg/m2, inclusive at screening.
- •4. All women of child bearing potential must practice effective contraception during the study and be willing and able to continue contraception for at least 90 days after the final administration of study treatment. All males must practice effective contraception and abstain from sperm donation during the study and be willing and able to continue contraception and abstention from sperm donation for at least 90 days after the final administration of study treatment.
- •5. Has the ability to communicate well with the investigator in the Dutch language and willing to comply with the study restrictions.
排除标准
- •1. A history of gastrointestinal disorder likely to influence drug absorption
- •2. Evidence of renal, hepatic, cardiovascular or metabolic dysfunction or any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator (following a detailed medical history, physical examination, vital signs (systolic and diastolic blood pressure, pulse rate, body temperature) and12-lead electrocardiogram (ECG)). Minor deviations from the normal range may be accepted, if judged by the investigator to have no clinical relevance.
- •3. Clinically significant abnormalities, as judged by the investigator, in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis). In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects.
- •4. Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
- •5. Use of melatonin (Circadin®, food supplement, pharmacy preparation) within 4 weeks before first dose administration.
- •6. Use of any medications (prescription or over-the-counter [OTC]), within 14 days of dose administration, or less than 5 half-lives (whichever is longer). An exception is paracetamol (up to 2 g/day). Other exceptions will only be made if the rationale is clearly documented by the investigator.
- •7. Use of any vitamin, mineral, herbal, and dietary supplements within 7 days of dose administration, or less than 5 half-lives (whichever is longer). Exceptions will only be made if the rationale is clearly documented by the investigator
- •8. Current or previous clinically relevant neurological disorders or neurosurgery.
- •9. Current or previous clinically relevant history of psychiatric disorders or sleep-wake disorders.
- •10. Current or previous clinically relevant history of drug or alcohol abuse.
- •11. Current or previous clinically relevant history of chronic headache or migraine.
- •12. A history of drug or food allergies or other clinically significant allergies (e.g. asthma, hay fever, neurodermatitis).
- •13. A history of hypersensitivity and/or idiosyncrasy to any of the test compounds or excipients employed in this study.
- •14. Participation in an investigational drug or device study within 3 months prior to dose administration or more than 4 times a year.
- •15. Night-shift worker or subjects with a significantly shifted diurnal activity pattern.
- •16. Subjects who have traveled across 3 different time zones within 1 week prior to screening or baseline.
- •17. Following a diet, e.g. kosher, halal, vegetarian, vegan or medically prescribed diet.
- •18. Positive test for drugs of abuse or alcohol at screening or pre-dose.
- •19. Smoker of more than 5 cigarettes per day within one month prior to screening or who use tobacco products equivalent to more than 5 cigarettes per day.
- •20. Excessive consumption of xanthine-containing products (more than eight cups of coffee or equivalent per day).
- •21. Loss or donation of blood over 500 mL within three months prior to screening.
- •22. If a woman: pregnant, breast-feeding, or planning to become pregnant during the study. <b
研究者
相似试验
已完成
不适用
A single dose, 4-way crossover, double-blind, placebo-controlled, randomized study to investigate the effect of JNJ-42847922 on polysomnography (PSG) measures in subjects with major depressive disorder with insomnia who are stably treated with antidepressants.Depression10027946InsomniaNL-OMON40706Janssen-Cilag10
已完成
1 期
Randomized, single dose, four period, cross-over open-label study to evaluate the pharmacokinetic parameters of 200 mg pirfenidone capsule versus pure pirfenidone 200 mg capsule (excluding excipients) versus 200 mg pirfenidone tablet versus 267 mg pirfenidone capsule in 32 healthy adults under fasting conditionsRespiratory - Other respiratory disorders / diseasesidiopathic pulmonary fibrosisACTRN12615000801516AFT Pharmaceuticals Ltd.32
已完成
1 期
Comparative assessment in healthy male volunteers under fasting conditions of the absorption and pharmacokinetics of 3 generic formulations of isotretinoin capsules against the innovator isotretinoin capsule in a pilot studyACTRN12615001083583Zenith Technology Corp Ltd15
进行中（未招募）
不适用
Relative bioavailability of oral suspension of rivaroxaban compared to standard tablethealthy volunteers (Prevention and teatment of thromboembolic disorders)MedDRA version: 14.1Level: LLTClassification code 10043640Term: Thrombosis venousSystem Organ Class: 100000004866EUCTR2013-001720-19-DEBayer HealthCare AG
进行中（未招募）
不适用
A double-blind, randomised, crossover, single dose, single centre, study examining the analgesic efficacy and tolerability of fixed-dose combinations of ibuprofen 200mg and acetaminophen 500mg, ibuprofen 400mg and acetaminophen 1,000mg and placebo in primary dysmenorrhoea. - Dysmenorrhoea Efficacy StudyPrimary DysmenorrhoeaMedDRA version: 9.1Level: LLTClassification code 10036689Term: Primary dysmenorrhoeaEUCTR2008-006762-29-GBReckitt Benckiser Healthcare (UK) Ltd